CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 44 enrolled
Drug / intervention
CABENUVAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04982445
NCT04982445Phase 4Completed
CompareCT.gov

A Phase 4, Open-label, Single Arm Study to Optimize Implementation of CABENUVA for the Treatment of HIV-1, for Administration in U.S. Community-based Infusion Centers or Other Alternate Sites of Administration

ViiV Healthcare·interventional·Posted Jul 29, 2021·Updated Apr 1, 2025

In Brief

A Phase 4 clinical trial evaluating CABENUVA for HIV Infections. Completed, enrolled 44 participants across 15 sites.

Detailed Summary

GLACIER (Giving Long Acting CABENUVA in an Infusion center/ASA) is an interventional study examining the administration of CABENUVA (Cabotegravir long acting \[LA\] plus Rilpivirine LA) intramuscular (IM) in infusion centers/ASAs in United States. In this study, the intervention is the process of using an infusion center/ASA as the location to receive the CABENUVA IM injections. The acceptability and feasibility of the IC/ASA to deliver CABENUVA IM injections will be assessed from the perspectives of the participants, HIV care providers and IC/ASA staff. In this study, Month 1 is the Baseline visit. CABENUVA is a registered trademark of ViiV Healthcare.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedJul 29, 2021
Enrollment StartNov 18, 2021
Primary CompletionJan 31, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.9 years ago

Interventions

CABENUVAdrug

CABENUVA will be administered IM at infusion centers/ASAs